Watchdog suggests stem cell policies for state
By San Diego Union Tribune,
San Diego Union Tribune
| 01. 23. 2006
A taxpayer watchdog group is expected to release a report today outlining how leaders of the state's $3 billion stem cell initiative could develop policies to make stem-cell-based therapies affordable and accessible to Californians.
Leaders of the initiative known as Proposition 71 "must put the interests of taxpayers and patients ahead of private biotech companies who have (a) financial stake in the outcome," the Foundation for Taxpayer and Consumer Rights said in its report.
For example, a portion of the money the state raises by licensing scientific discoveries made with Proposition 71 funds should be used to make new therapies available to people who can't afford them, the foundation report states.
Biotechnology or pharmaceutical companies that develop therapies using science that results from Proposition 71 should be required to sell those therapies to California at their lowest price, the report states.
It also recommends that the institute reserve the right to keep a Proposition 71-funded discovery from being patented if it is determined that it would do more good by remaining in the public domain.
In addition, it suggests that...
Related Articles
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...
By Sarah Kliff and Azeen Ghorayshi, The New York Times | 07.15.2024
By Katie LaGrone, WPTV | 06.28.2024
Image by National Cancer Institute from Unsplash
TAMPA, Fla. — A Tampa jury recently found the now-defunct Lung Institute in Tampa guilty of engaging in “deceptive or unfair practices” while it offered customers “valueless” stem cell therapy to treat incurable...